Related Experiment Video
Updated: May 4, 2026
05:05
Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
12.0K
Alogliptin.
Dennis J Cada1, Terri L Levien2, Danial E Baker3
1Founder and Contributing Editor, The Formulary ;
Hospital Pharmacy
|January 15, 2014
Summary
The Formulary Monograph Service provides monthly drug monographs for Pharmacy & Therapeutics Committees, including new drug evaluations and utilization reviews. This service aids in informed medication management and formulary decisions.
Area of Science:
- Pharmacology
- Drug Information Services
- Clinical Pharmacy
Background:
- The Formulary Monograph Service offers detailed drug information for healthcare professionals.
- It targets Pharmacy & Therapeutics Committees, providing essential data for formulary decisions.
Purpose of the Study:
- To deliver timely and comprehensive drug monographs for newly released and late-stage trial medications.
- To support drug utilization evaluations (DUE/MUE) and provide concise summaries for pharmacy and nursing staff.
Main Methods:
- Publication of 5-6 detailed monographs per month covering new and investigational drugs.
- Inclusion of a monthly drug class review and a comprehensive DUE/MUE.
- Dissemination of information via print and online formats, with customization options.
Main Results:
- Subscribers receive up-to-date information on drugs such as prothrombin complex concentrate, cysteamine bitartrate, and sofosbuvir.
- Monthly DUE/MUE focuses on specific agents, with July 2013 highlighting canagliflozin.
- Accessible summaries are provided for pharmacy and nursing in-service needs.
Conclusions:
- The service facilitates informed decision-making for Pharmacy & Therapeutics Committees.
- It enhances medication management through regular updates and evaluations.
- Customizable content and diverse formats ensure utility for various healthcare settings.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953